Norwich Expands Focus on Business Development

New expertise, leadership will drive growth in key markets

Norwich, New York - July 12, 2011 - Norwich, a provider of full-service contract development and manufacturing for the pharmaceutical and biotech industry, today announced the addition of three business development leaders. Mitchell Winfree has been appointed Vice President, Business Development, while Gregory Downs and Bob Peoples both have joined the company in the role of Director, Business Development.

Mitchell Win free joins Norwich Clinical Services to develop and lead the regional expansion for the CRO business in North America. Winfree brings a track record for leading successful business development operations for both large, global CROs as well as smaller, therapeutically focused providers. He possesses nearly 20 years'experience in discovery, pre-clinical, and clinical research that has been demonstrated through career achievements with PPD, Rho, and Clinsys Clinical Research. Winfree earned a B.S. degree in Biology with a minor in Genetics from North Carolina State University.

Gregory Downs joins Norwich with more than 15years of pharmaceuticals, clinical testing and development sales experience, with additional expertise in clinical pharmacy and analytical testing. He is responsible for expanding Norwich operations in the northeast United States and eastern Canada. Downs began his career in clinical pharmacy and analytical testing and he has since held leadership positions in business development with Azopharma, Biovail and Aurobindo Pharma. Downs holds a B.S. degree in Biology with a minor in Chemistry from Campbell University.

Bob Peoples has more than 25 years' experience in pharmaceutical manufacturing, sales and marketing, and he will be responsible for growing Norwich business in the southeast United States. He has directed manufacturing and packaging operations at Burroughs Welcome and DSM Pharmaceuticals and has spent the last 10 years in sales and customer service.Peoples earned a B.S. in Business Administration from East Carolina University.

"We're extremely pleased to welcome Mitchell, Greg and Bob to Norwich," said Terry Novak, president of Norwich Pharmaceuticals. "Their leadership will be instrumental as Norwich further expands our capability to provide customers with one comprehensive solution for all stages of the product lifecycle."

About Norwich

Norwich is a full-service contract development and manufacturing provider for Rx and OTC pharmaceuticals. Norwich applies more than 120 years of experience and an unparalleled compliance record to offer customers greater flexibility, resources and speed that result in a streamlined progression from product development to scale-up and commercial manufacturing through clinical services. Visit www.norwichpharma.com foradditional information.

Suggested Articles

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.

Less than two years after taking the reins from founding chief Rusty Williams, Five Prime Therapeutics CEO Aron Knickerbocker is exiting the company.

The RV144 HIV vaccine regimen containing clades B and E inserts produced strong immune responses in South Africa, where clade C dominates.